



#14
8/14/01
B
VIA HAND DELIVERY AUGUST 3, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Hastings et al.

Attorney Docket No.: PF487

Application Serial No.: 09/466,778

Art Unit: 1653

Filed: December 20, 1999

Examiner: Mitra, R.

Title: Novel Hyaluronan-Binding Proteins and Encoding Genes

RECEIVED

AUG 07 2001

TECH CENTER 1600/2900

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR 1.97**

Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys and/or Agents for Applicants hereby direct the Examiner's attention to references AD to AF listed on the attached Form PTO/SB/08. A copy of each reference is enclosed.

The listed references are presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) concerning the Examiner's duty to consider and use any such information. Applicants respectfully request that the Examiner make the listed references of record in the file history of the application, and consider the information contained therein during the prosecution of this application.

Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such

08/07/2001 MWOLDER1 00000037 083425 09466778

01 FC:126 100.00 CH


references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to take appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Applicants believe that this Information Disclosure Statement is being filed after the period specified in 37 C.F.R. § 1.97(b), but before the mailing date of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application. Pursuant to 37 C.F.R. § 1.97(c), the Patent and Trademark Office will consider this Information Disclosure Statement if it is accompanied by either a statement as specified in 37 C.F.R. § 1.97(e) or the fee as specified in 37 C.F.R. § 1.17(p).

Accordingly, the Commissioner is hereby authorized to charge Deposit Account No. 08-3425 in the amount of \$180.00 as payment of the fee required under 37 CFR § 1.17(p). The Commissioner is also authorized to charge any additional required fee or credit any overpayment in connection with this submission to our Deposit Account No. 08-3425.

Respectfully submitted,

Dated: August 3, 2001


Mark J. Hyman (Reg. No. 46,789)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Telephone: (240) 314-1224

Enclosures